Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIP4K2A | P48426 | 4/20 | 0.45 |
| ▸ | PIP4K2B | P78356 | 4/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 9/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.42 |
| ▸ | CLK1 | P49759 | 1/20 | 0.42 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.42 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3765367 | 0.84 | MAPK10 (0.44) | MAPK10DYRK1BDYRK1ACLK1DYRK2 | |
| SCHEMBL16143779 | 0.78 | MAPK10 (0.39) | MAPK10DYRK1BDYRK1ACLK1DYRK2 | |
| SCHEMBL2452363 | 0.77 | MAPK10 (0.46) | MAPK10DYRK1BDYRK1ACLK1DYRK2 | |
| SCHEMBL3727490 | 0.77 | CYP3A4 (0.41) | MAPK10DYRK1BDYRK1ACLK1DYRK2 | |
| SCHEMBL1702596 | 0.77 | CYP3A4 (0.41) | MAPK10DYRK1BDYRK1ACLK1DYRK2 | |
| SCHEMBL1703190 | 0.77 | CYP3A4 (0.41) | MAPK10DYRK1BDYRK1ACLK1DYRK2 | |
| SCHEMBL1702764 | 0.77 | CYP3A4 (0.57) | PIP4K2APIP4K2BMAPK10DYRK1BDYRK1A | |
| SCHEMBL29461413 | 0.77 | CYP3A4 (0.41) | MAPK10DYRK1BDYRK1ACLK1DYRK2 | |
| SCHEMBL1702454 | 0.76 | KIF11 (0.47) | MAPK10DYRK1BDYRK1ACLK1DYRK2 | |
| SCHEMBL1702892 | 0.76 | DYRK1B (0.46) | PIP4K2APIP4K2BMAPK10DYRK1BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440528-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-10-08 | — | — | EP | claimed |
| EP-2440528-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-04-18 | — | — | EP | claimed |
| WO-2010142656-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | WO | claimed |
| US-20100311760-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | DE VICENTE FIDALGO JAVIER | 2010-12-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311760-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, XDH, GTF3C4 | PIP4K2A 2111/4885PIP4K2B 1750/4885MAPK10 3770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.